Pravachol Rx Interaction Profile Is Viewed Favorably In Statins OTC Review
Executive Summary
The drug interaction profile of Bristol-Myers Squibb's Pravachol may make the cholesterol-lowering agent a more attractive OTC switch candidate than Merck's Mevacor, members of the statin OTC switch advisory committee suggested.
You may also be interested in...
Statin Class Labeling Should Include Liver Failure As Adverse Event - OPDRA
Class labeling for HMG-CoA reductase inhibitors should be updated to include liver failure as an adverse event, an Office of Postmarketing Drug Risk Assessment safety review concludes.
Statin Class Labeling Should Include Liver Failure As Adverse Event - OPDRA
Class labeling for HMG-CoA reductase inhibitors should be updated to include liver failure as an adverse event, an Office of Postmarketing Drug Risk Assessment safety review concludes.
Bristol Pravachol OTC Label Studies, Redefined Population Urged By Cmte.
Bristol-Myers Squibb's Pravachol (pravastatin) 10 mg is an attractive candidate for OTC status, but the company should first conduct additional label comprehension studies and better define the target population for the cholesterol agent, FDA advisory committee members suggested July 14.